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 Transforming growth factor- β (TGF- β ) is 
a well-established profi brotic cytokine 
that is activated and / or upregulated in the 
course of glomerular injury. Both mesang-
ial cells and podocytes in the glomerulus 
of the kidney respond to TGF- β by acti-
vating profi brotic and proapoptotic sign-
aling. TGF- β exerts its functions via 
activation of the serine / threonine kinase 
TGF- β receptors I (T β RI) and II (T β RII). 1 
Binding of TGF- β to the constitutively 
active T β RII leads to phosphorylation and 
activation of T β RI. Th e activated T β RI 
initiates Smad-dependent and -independ-
ent signaling. In Smad-dependent signal-
ing, serine phosphorylation of Smad2 
and / or Smad3 occurs, resulting in their 
association with Smad4, translocation to 
the nucleus, and transcription of target 
genes. In Smad-independent signaling, 
adaptor proteins can associate with T β RI 
or T β RII, promoting the activation of 
pathways such as MAPK, PP2A, JNK, and 
p38 MAPK. Some of these pathways regu-
late Smad activation, while others induce 
responses unrelated to transcription, 
including cell growth and migration. Both 
Smad-dependent and -independent path-
ways have been implicated in the develop-
ment and progression of fibrosis, and 
inhibition of TGF- β ameliorates glomeru-
losclerosis following injury. In addition to 
the kinases indicated above, TGF- β can 
aff ect cell function by cross-talking with 
phosphatidylinositol-3 – kinase (PI3  K). 
Th e observation that PI3K is a key down-
stream player in TGF- β -mediated signal-
ing comes from studies showing that this 
kinase is required for TGF- β -dependent 
upregulation of lysyl oxidases and mono-
cyte migration, as well as epithelial-to-
mesenchymal transition. 2,3 Finally, 
high-glucose-mediated activation of PI3  K 
is a key step in promoting TGF- β synthe-
sis, 4 clearly indicating a requirement 
of PI3  K for both TGF- β synthesis and 
function. 
 Th e PI3  K family of enzymes comprises 
eight catalytic isoforms subdivided into 
three classes: I, IA, and IB. Th e catalytic 
PI3  K isoforms can be regulated by recep-
tor tyrosine kinases and / or G protein-
coupled receptors and activate AKT, 
serum / glucocorticoid-regulated kinase 
(SGK), phosphoinositide-dependent 
kinase 1 (PDK1), mammalian target of 
rapamycin (mTOR), and several other 
pathways that control a variety of cellular 
processes, including proliferation, growth, 
apoptosis, migration, and metabolism. 5 In 
addition to kinase-mediated signaling, 
some PI3  K isoforms also serve as scaf-
folds with kinase-independent signaling 
functions. Th e class IB catalytic subunit 
(p110  ) associates with the p101, p87, or 
p84 regulatory subunits, and it is usually 
activated by G protein-coupled receptors. 
Th is catalytic subunit is highly expressed 
in hematopoietic cells and plays a 
major role in regulating proinfl ammatory 
signaling. Recently, a role of p110  in 
non-hematopoietic cells in the control 
of insulin resistance and  β -adrenergic 
receptor function was suggested. 6,7 
However, whether glomerular cells 
express this catalytic isoform, whether 
this isoform contributes to glomerular 
injury, and whether p110  is a down-
stream eff ector of TGF- β have not been 
investigated. 
 Finer and colleagues 8 (this issue) 
describe selective and temporal roles of 
p110  and TGF- β in regulating adriamy-
cin-mediated glomerular injury. Adri-
amycin is a well-established rodent model 
of chronic kidney disease. Adriamycin 
leads to podocyte injury followed by 
glomerulosclerosis, tubulointerstitial 
fi brosis, and end-stage kidney disease. 
BALB / c mice are susceptible to adriamy-
cin-mediated injury and develop classical 
focal segmental glomerulosclerosis. 9 
However, two problems related to the use 
of BALB / c mice are that, following adri-
amycin treatment, they develop a diff use 
and aggressive pattern of injury, and that 
they oft en recover within 8 weeks aft er 
injury. Finer and colleagues provide 
evidence that 129x1 / SvJ mice represent 
a better model to study adriamycin neph-
ropathy, as they develop proteinuria, 
nephrotic syndrome, and glomerular and 
tubulointerstitial accumulation of extra-
cellular matrix components sequentially 
after adriamycin administration. 8 
Th us, this model allows a better sequential 
and temporal analysis of pathways 
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activated in the early versus late stages of 
renal injury. 
 On the basis of the finding that 
increased expression of TGF- β has been 
observed in many models of glomerular 
injury, including adriamycin nephropathy, 
the authors analyze the eff ect of a soluble 
T β RII antagonist on both adriamycin-
mediated fi brosis and proteinuria. Th e 
authors provide evidence that inhibiting 
TGF- β reduces fi brosis, without aff ecting 
proteinuria. 8 Th is surprising result sug-
gests that pathways classically activated by 
TGF- β do not contribute to the damage of 
the glomerular fi ltration barrier in this 
injury model. Importantly, selective inhi-
bition of the p110  isozyme of PI3  K with 
AS605240 reduces adriamycin-mediated 
proteinuria and injury, suggesting that 
this kinase contributes to podocyte injury. 
Th is is an interesting fi nding, as the p110  
isoform is particularly highly expressed in 
lymphoid cells, with low to modest expres-
sion in other organs. Th e contribution of 
p110  in adriamycin nephropathy is cor-
roborated by the finding that  in vivo 
upregulation of p110  by podocytes coin-
cides with concomitant downregulation 
of nephrin immediately after injury. 8 
Treatment with AS605240 prevents 
nephrin downregulation  in vivo as well as 
cytoskeletal disorganization and podocyte 
apoptosis  in vitro , clearly suggesting that 
upregulation of p110  by podocytes plays 
a deleterious role by contributing to loss 
of the glomerular fi ltration barrier and 
proteinuria. 
 Th e fi ndings of Finer and colleagues 8 
suggest that adriamycin regulates both 
podocyte and non-podocyte targets (that 
is, p110  and TGF- β , respectively). In 
addition to podocytes, mesangial cells are 
a target of adriamycin both  in vivo and 
 in vitro . In this context, it has been shown 
that adriamycin leads to  in vivo mesangio-
lysis as early as 48  h of treatment and 
increases mesangial production of 
reactive oxygen species and matrix depo-
sition. 10 Reactive oxygen species can 
upregulate the expression of various 
growth factors and cytokines, including 
TGF- β . Th us, adriamycin might contrib-
ute to the fi brotic phenotype predomi-
nantly by targeting the mesangial 
cell – TGF- β axis, and to proteinuria pre-
dominantly by targeting the podocyte –
 p110  axis ( Figure 1 ). 
 In an attempt to determine what path-
way is activated fi rst in the course of adri-
amycin-mediated injury, Finer and 
colleagues analyzed TGF- β expression 
and the contribution of p110  at early 
stages of injury. Th ey provide evidence 
that proteinuria is evident as early as 3 
days aft er adriamycin injection; however, 
the levels of TGF- β mRNA increase at 
later stages aft er injury. 8 Th us, proteinuria 
precedes TGF- β synthesis. Interestingly, 
early treatment with AS605240 prevents 
adriamycin-mediated proteinuria as well 
as matrix deposition and synthesis, sug-
gesting either that p110  has a direct 
profi brotic role or that it might control 
TGF- β synthesis or function. Th e latter 
possibility is supported by the fact that, 
although PI3  K may contribute to TGF-
 β -mediated profi brotic signaling, either 
p110  activity or the resulting down-
stream proteinuria controls TGF- β pro-
duction. Previous studies by the authors 
showed that PI3  K plays a direct role in 
TGF- β -stimulated mesangial-cell fi bro-
genic signaling. Using a general inhibitor 
of PI3  K (LY294002) and the selective 
p110  inhibitor AS605240, the authors 
elegantly showed that only LY294002, but 
not AS605240, prevents TGF- β -mediated 
collagen synthesis in renal cells. 8 This 
result allowed the authors to conclude 
that p110  does not directly control 
matrix deposition nor is it a downstream 
mediator of TGF- β signaling. Conversely, 
a PI3  K isoform other than p110  contrib-
utes to mesangial-cell fi brogenesis. 
 A possible explanation for the benefi cial 
eff ects of AS605240 is that its antifi brotic 
action might be due to its ability to 
negatively regulate TGF- β production. 
Consistent with this hypothesis, adriamy-
cin-mediated TGF- β production  in vivo 
is blunted by AS605240 treatment. 8 How-
ever, given the inhibition of proteinuria by 
AS605240, and the time delay between 
p110  -mediated podocyte injury (3 days 
aft er injury) and the peak of TGF- β pro-
duction (12 – 14 days after injury), it is 
possible, even likely, that p110  does not 
directly regulate TGF- β , but that such 
production is in some way mediated by 
podocyte injury or subsequent protein uria 
( Figure 1 ). 
 Although this study clearly shows that 
selective isozymes of the PI3  K family con-
trol podocyte function and stability, a 
shortcoming is that the authors analyzed 
only one model of glomerular injury, thus 
making it diffi  cult to determine whether 
upregulation of p110  is restricted to adri-
amycin-mediated injury or whether it is 
more generally observed in other models 
of podocyte injury. It would also be inter-
esting to determine whether and when 
activation or upregulation of this selective 
isozyme becomes evident in human renal 
disease, as it would make p110  a desira-
ble and selective target for renal injury. 
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 Figure 1  |  Possible mechanism whereby adriamycin contributes to glomerular injury. 
Schematic representation of podocytes and mesangial cells in healthy conditions ( a ) and after 
exposure to adriamycin ( b ). Adriamycin leads to upregulation of the p110  catalytic isoform of 
PI3  K in podocytes with concomitant loss of nephrin, cytoskeletal disorganization, and apoptosis 
(1). This, in turn, leads to proteinuria, more injury, and increased expression of TGF-  by mesangial 
cells with consequent fibrosis (2). Adriamycin can also directly affect mesangial cells by promoting 
proliferation and generation of profibrotic reactive oxygen species (ROS) (3). 
commentar y
Kidney International (2012) 82     509
 Despite these shortcomings, the novelty 
of this paper can be summarized as fol-
lows: (1) Th e authors provide evidence 
that the 129x1 / SvJ mouse is susceptible to 
adriamycin-mediated nephropathy and 
suggest that this model can be used to 
study the temporal changes that occur 
in focal segmental glomerulosclerosis. 
(2) Th is is the fi rst demonstration that 
p110   , an isoform of PI3  K that is 
expressed by lymphatic cells, is upregu-
lated in injured podocytes both  in vivo 
and  in vitro . (3) Th is PI3  K isoform con-
tributes to podocyte injury by downregu-
lating nephrin expression and altering the 
cytoskeleton. (4) Selective blockade 
of p110  ameliorates early proteinuria 
before upregulation of TGF- β is evident. 
(5) Th e authors demonstrate a selective 
function for TGF- β versus p110  in 
 driving  adriamycin-mediated injury. 
Th us, this study shows that proteinuria 
and renal fibrogenesis involve distinct 
cell types and signaling mechanisms 
( Figure 1 ), and suggests that inhibiting 
p110  might have a better overall benefi -
cial effect than traditional anti-TGF- β 
therapy early in the disease course. 
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 Role changes of   -catenin in 
kidney injury and repair 
 Jianping  Peng 1 , 2 and  Zheng  Dong 1 , 3 
 Using conditional knockout models, Zhou  et al. firmly establish a 
renoprotective role of   -catenin in acute kidney injury. Although 
  -catenin is protective at the injury phase, whether it helps kidney 
repair remains in question. In a renal cell scratch model,   -catenin 
suppresses wound healing. Moreover, continuous activation of   -
catenin may lead to renal fibrosis. Further investigation should elucidate 
the distinct roles played by   -catenin and related signaling in kidney 
injury, repair, and fibrosis. 
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  -catenin and related signaling play an 
active role in nephron formation in the 
early stage of kidney development; how-
ever, it is largely silent in adult kidneys. 
Nonetheless, this signaling pathway is 
activated in kidney tubules, podocytes, 
and interstitial cells under numerous dis-
ease conditions, including diabetic neph-
ropathy, cystic kidney disease, and acute 
kidney injury (AKI), just to name a few. 
Despite these observations, the patho-
logical role played by   -catenin in kidney 
diseases is poorly understood. Using a 
conditional knockout mouse model, Zhou 
and colleagues 1 (this issue) have now 
demonstrated compelling evidence for a 
renoprotective role of   -catenin in AKI. 
 In this study,   -catenin was fi rst shown 
to be markedly induced in kidney tubules 
in a nephrotoxic AKI model of folic acid 
treatment. 1 To demonstrate the patho-
logical role of   -catenin, a conditional 
knockout model was then established, in 
which   -catenin was ablated specifi cally 
from kidney tubules by the crossing of 
Ksp-Cre mice with   -catenin-fl oxed ani-
mals. The mice from this conditional 
knockout model showed significantly 
more severe AKI aft er folic acid treatment. 
Compared with wild-type, the knockout 
mice had a higher morta-lity rate, severer 
tissue damage, more renal apoptosis, and 
heightened renal failure. Consistently, 
these animals were more sensitive to AKI 
induced by renal ischemia – reperfusion. 
Mechanistically,   -catenin knockout 
kidney tissues showed an upregulation of 
proapoptotic genes, such as p53 and Bax, 
and a decrease in survival factors, includ-
ing survivin and phosphorylated Akt. 
